Q1 2025 Shilpa Medicare Ltd Earnings Call Transcript
Key Points
- Shilpa Medicare Ltd (BOM:530549) reported a 15% year-on-year growth in top-line revenue, reaching INR302 crores.
- The company achieved a gross profit margin of 68%, up from 66% in the same quarter last year.
- EBITDA for the quarter increased by 66% year-on-year, reaching INR83 crores, with EBITDA margins improving to 28% from 19%.
- The company has secured prelaunch orders for two NDA molecules in the oncology segment, indicating strong future revenue potential.
- Shilpa Medicare Ltd (BOM:530549) successfully completed the ANVISA-Brazil GMP audit for 29 products, opening opportunities in the Brazilian market.
- The US formulation segment saw a significant decline, dropping from INR30 crores to INR10 crores quarter-on-quarter.
- The company faces high tax rates, with an expected rate of around 35% for FY25.
- There is uncertainty regarding the commercialization timeline for some key products, including the breakthrough designation NDA molecule.
- The company has a high net debt of INR514 crores as of June 30, 2024, despite a reduction from INR912 crores at the end of March 2024.
- The albumin product's excipient grade market entry is still in early stages, with no clear timeline for significant sales.
Ladies and gentlemen, good day, and welcome to the Shilpa Medicare earnings call. (Operator Instructions)
Please note that this conference is being recorded. I now hand the conference over to Ms. Runjhun Jain from EY IR. Thank you, and over to you.
Thank you, Raj. A warm welcome to all the participants to the Q1 FY25 earnings call of Shilpa Medicare Limited. The financial results and the presentation have been uploaded on the company's website and on the exchanges. Please note that this conference is being recorded and the transcript, along with audio of the same, will be made available on the website of the company as well as the exchanges.
I would like to remind you that today's discussion might include forward-looking statements based on the current expectations and assumptions. These statements are subject to risks and uncertainties that could cause actual results to differ materially. Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
